News

Bringing It All Back Home: Reshaping Ophthalmology's Clinic with Home OCT

December 11th 2024

Real-world clinical data from the Adelphi PNH II Disease Specific Programme were reported at ASH 2024.

By Connor Iapoce

December 11th 2024

The FDA-approved Scanly, a home-based OCT device, revolutionizes nAMD care by empowering patients with self-monitoring and enhancing personalized treatment.

Hubert Schrezenmeier, MD, professor, Institute of Transfusion Medicine, Ulm University, Germany

Danicopan a Safe Option for Breakthrough Bleeds in PNH

Study Highlights Advances in Understanding Risk, Prevention Measures for Atopic Dermatitis

Danicopan add-on therapy demonstrated more favorable safety in the ALPHA trial than pegcetacoplan did in the PEGASUS trial in a new analysis.

Study Identifies Depression Treatment Gaps by Ethnicity, Age, Suicidal Risk

Investigators looked at the effects of the exposome among patients with atopic dermatitis in order to better understand the influence of such elements as obesity and microorganisms.

Maria E. Garcia, MD I University of California, San Francisco

PRICE-2: Hypovolaemic Phlebotomy Reduces Blood Transfusions After Liver Resection

A study found only 38% of patients in the large US academic health system screened for depression received antidepressants or mental health referrals.

Guillaume Martel, MD, MSc | Credit: The Ottawa Hospital

By Abigail Brooks, MA

The Long COVID Patient Journey: A Complex and Uncertain Road

Hypovolaemic phlebotomy reduced perioperative blood transfusion and improved operative conditions versus usual care in patients undergoing liver resection.

By Sophia Abene

Study Finds Bimekizumab Improves Genital, Scalp, Nail Psoriasis at 52 Weeks

Navigating the long road of Long COVID requires more than just recovery from an infection, it demands specialized, multifaceted care to address persistent and often invisible neurological symptoms.

Adults aged 50 – 80 years Often Experience Loneliness, Social isolation

These 52-week data highlight bimekizumab’s efficacy in the scalp, nail, and genital region for psoriasis, along with Dermatology Life Quality Index (DLQI) improvements.

Credit: Preeti N. Malani, MD I University of Michigan

Marlyn Mayo, MD: Improving Pruritus Management in PBC Care

A recent study found that loneliness among adults aged 50 – 80 increased from 2018 to 2022 and dropped in 2023 and 2024.

By Abigail Brooks, MA
Marlyn Mayo, MD

Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH

Mayo explains current shortcomings of pruritus care in PBC and what the additions of elafibranor, seladelpar, and other agents in development may offer.

By Abena Appiah-Kubi, MD, MPH
Victoria Johnson

Steven W. Pipe, MD: Fitusiran With Anti-Thrombin Modulation Yields Effective Bleed Control, Reduces Infusions for Hemophilia

Appiah-Kubi also noted that despite elevated HbF levels, very young children with SCA already had anemia and reticulocytosis.

By Victoria Johnson
Steven W. Pipe, MD

Highlighting the Danger of SCI Progression during iTTP Remission, with Shruti Chaturvedi, MBSS, MS

Pipe discussed findings from the open-label extension of the ATLAS studies at ASH 2024.

By Victoria Johnson
Shruti Chaturvedi, MBBS, MS

Atogepant Improves Quality of Life in Individuals with Chronic, Episodic Migraine

Chaturvedi discussed findings from the NeST study at ASH 2024, including an increased risk of stroke in those with silent cerebral infarction progression.

Credit: Christopher Gottschalk, MD I Yale Medicine

HepB-CpG Offers Superior Seroprotection in People with HIV, Prior HBV Vaccine Nonresponse

A recent study examined the phase 3 trials ADVANCE, PROGRESS, and ELEVATE and saw atogepant 60 mg as a preventive migraine treatment improves quality of life and functioning.

Kristen Marks, MD | Credit: Weill Cornell

By Abigail Brooks, MA

Autonomic Modulation May Benefit Patients with Constipation-Predominant IBS

HepB-CpG achieved superior seroprotection response versus conventional HepB-alum in patients with HIV and nonresponse to prior hepatitis B vaccination.

Allison Malcolm, MBBS | Credit: Forster Private Hospital

By Abigail Brooks, MA

2024 State of Lung Cancer: The Hopes and Hurdles of Precision Oncology with Jacob Sands, MD

Study findings highlight systemic and local autonomic imbalance in patients with IBS-C, pointing to the value of autonomic modulation in this population.

Sexual and Physical Assaults are Common Life Stressors for Women in Iceland, Linked to PTSD

In this month's episode of Lungcast, Jacob Sands, MD, discusses the American Lung Association’s recently newly-released 2024 State of Lung Cancer report.

Edda Bjork Thordardottir, PhD I ResearchGate

Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy

A study found 66.4% of participants with probable PTSD had a life stressor of unwanted sexual experiences.

By Caroline Piatek, MD
Victoria Johnson

Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy

Piatek shared the latest data update from the phase 3 ALPHA study at the ASH 2024.

By Victoria Johnson
Haydar Frangoul, MD, MS

Eltrombopag Bests Standard of Care as First-Line Therapy in Pediatric Immune Thrombocytopenia

Frangoul discussed highlights from the latest data update from the CLIMB SCD-121 trial of Casgevy.

Kristin Shimano, MD | Credit: UCSF Benioff Children's Hospitals

By Patrick Campbell

Universal 25 µg/L Threshold for Iron Deficiency is Cost-Effective, Could Improve Management in US Women

Data from the PINES trial at ASH 2024 suggest eltrombopag could outperform current standard of care for platelet response in newly diagnosed pediatric ITP.

Female patient discussing iron deficiency with care provider. | Credit: Shutterstock

By Patrick Campbell

GLP-1 Receptor Agonists Could Reduce Stroke Risk in Type 2 Diabetes

Yale study at ASH 2024 finds screening adult women for iron deficiency with a ferritin threshold of 25 µg/L is cost-effective.

By Patrick Campbell

Hydroxyurea Shows Clinical Benefit in HbSC, Misses the Mark on Safety

A propensity score-matched study from ASH 2024 suggests GLP-1 RA use reduced VTE risk in type 2 diabetes.

Yvonne Dei-Adomakoh, MBBS, hematologist at the University of Ghana Medical School Korle Bu Teaching Hospital in Accra, Ghana

FDA News Month in Review: November 2024

While the therapy was generally well-tolerated, the PIVOT trial failed its primary endpoint of dose-limiting toxicities.

Etavopivat Well-Tolerated With Some Disease-Modifying Activity in SCD

This new edition of HCPLive’s monthly newsletter on recent US Food and Drug Administration (FDA) news features highlighted updates from across therapeutic pipelines.

Julie Kanter, MD, director, Adult Sickle Cell Clinic and associate professor, Division of Hematology and Oncology, University of Alabama – Birmingham

Rilzabrutinib Improves Platelet Response, Quality of Life in Immune Thrombocytopenia Compared to Placebo

The therapy uses a novel pyruvate kinase activator mechanism and warrants further investigation in an ongoing phase 3 trial.

David J. Kuter, MD, DPhil, program director of hematology at Massachusetts General Hospital and professor of medicine at Harvard Medical School in Boston

Rheumatology Month in Review: November 2024

Notably, participants without platelet responses also experienced improvements in fatigue, which may be due to the monoclonal antibody’s anti-inflammatory action.

No Link Found Between Allergic Reaction Severity and Allergen Amount

The rheumatology month in review emphasizes new data from ACR 2024 in lupus, gout, and fibromyalgia.

Psychiatry Month in Review: November 2024

December 6th 2024

In this analysis, investigators determined that the eliciting dose of an allergen may be an unpredictable marker for the severity of an allergic reaction.